DE602007004570D1 - Verwendung von Nogo-C bei der Beurteilung von Herzversagen - Google Patents

Verwendung von Nogo-C bei der Beurteilung von Herzversagen

Info

Publication number
DE602007004570D1
DE602007004570D1 DE602007004570T DE602007004570T DE602007004570D1 DE 602007004570 D1 DE602007004570 D1 DE 602007004570D1 DE 602007004570 T DE602007004570 T DE 602007004570T DE 602007004570 T DE602007004570 T DE 602007004570T DE 602007004570 D1 DE602007004570 D1 DE 602007004570D1
Authority
DE
Germany
Prior art keywords
nogo
heart failure
marker
concentration
evaluation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007004570T
Other languages
English (en)
Inventor
Dirk Block
Georg Hess
Hendrik Huedig
Der Eltz Herbert Von
Ursula-Henrike Wienhues-Thelen
Andrew Emili
Vincent Fong
Anthony Gramolini
Ruth Isserlin
Thomas Kislinger
Peter Liu
David Maclennan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Toronto
Roche Diagnostics GmbH
Original Assignee
University of Toronto
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Toronto, Roche Diagnostics GmbH filed Critical University of Toronto
Publication of DE602007004570D1 publication Critical patent/DE602007004570D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
DE602007004570T 2007-03-06 2007-03-06 Verwendung von Nogo-C bei der Beurteilung von Herzversagen Active DE602007004570D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07004532A EP1967853B1 (de) 2007-03-06 2007-03-06 Verwendung von Nogo-C bei der Beurteilung von Herzversagen

Publications (1)

Publication Number Publication Date
DE602007004570D1 true DE602007004570D1 (de) 2010-03-18

Family

ID=38124144

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007004570T Active DE602007004570D1 (de) 2007-03-06 2007-03-06 Verwendung von Nogo-C bei der Beurteilung von Herzversagen

Country Status (4)

Country Link
EP (1) EP1967853B1 (de)
AT (1) ATE456797T1 (de)
DE (1) DE602007004570D1 (de)
ES (1) ES2339284T3 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2498095A3 (de) * 2007-01-25 2012-11-28 Roche Diagniostics GmbH Verwendung von IGFBP-7 bei der Beurteilung von Herzversagen
US20090286256A1 (en) * 2008-05-19 2009-11-19 Abbott Laboratories Isolated human autoantibodies to natriuretic peptides and methods and kits for detecting human autoantibodies to natriuretic peptides
ES2607491T3 (es) * 2009-04-27 2017-03-31 F. Hoffmann-La Roche Ag Uso de endostatina como marcador de la insuficiencia cardíaca
JP5592487B2 (ja) * 2009-07-27 2014-09-17 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 心不全の評価におけるミメカンの使用
CN113449757A (zh) * 2020-03-26 2021-09-28 太原理工大学 心衰诊断模型的构建方法、构建系统和心衰诊断装置

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6461828B1 (en) * 2001-09-04 2002-10-08 Syn X Pharma Conjunctive analysis of biological marker expression for diagnosing organ failure

Also Published As

Publication number Publication date
EP1967853A1 (de) 2008-09-10
ATE456797T1 (de) 2010-02-15
ES2339284T3 (es) 2010-05-18
EP1967853B1 (de) 2010-01-27

Similar Documents

Publication Publication Date Title
WO2008089994A8 (en) Use of igfbp-7 in the assessment of heart failure
ATE468537T1 (de) Neurodegenerative marker für depression.
ATE514755T1 (de) Fluoreszenzfarbstoffe zur verwendung bei der glukoseerfassung
WO2011012268A8 (en) Use of mimecan in the assessment of heart failure
ATE511656T1 (de) Verfahren zur risikobewertung von herzeingriffen auf gdf-15-basis
BRPI0618391A2 (pt) método para identificar um nucleotìdeo individual, método para seqüenciar uma seqüência de ácido nucleico alvo, e, kit para seqüenciar um ácido nucleico
ATE430936T1 (de) Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome
WO2008148072A3 (en) Disease-associated genetic variations and methods for obtaining and using same
ATE480643T1 (de) Homogener nachweis von analyten
WO2006113245A3 (en) Methods for measuring glycan levels of proteins
ATE415662T1 (de) Bestimmung der tatsächlichen zeit, die ein prozessor bei der ausführung eines codeteiles aufwendet
ATE548467T1 (de) Verfahren zur identifizierung von biomarkern mit eignung bei der diagnose biologischer zustände
WO2007134235A3 (en) Hla alleles associated with adverse drug reactions and methods for detecting such
EP1996718A4 (de) Toxizitätsscreeningverfahren
HK1149956A1 (en) Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex
DE602007004570D1 (de) Verwendung von Nogo-C bei der Beurteilung von Herzversagen
ATE495243T1 (de) Verfahren zur herstellung von hochempfindlichen endonukleasen, neuartige zubereitungen von nukleasen und ihre verwendung
ATE482398T1 (de) Verfahren zur stratifizierung von herzinsuffizienz
ATE454632T1 (de) Verfahren zur beurteilung der lebensfähigkeit von embryos
DE60315715D1 (de) Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs
ATE468535T1 (de) Verwendung von nnmt als marker für lungenkrebs
DE602006021131D1 (de) Verfahren zur Bestimmung des Phänotyps von Zellen
ATE539163T1 (de) Auf der verwendung von mva beruhende impfstoffe
ATE426168T1 (de) Verwendung von asc als marker fur kolorektalkarzinome
WO2010000467A8 (en) Asc as a marker for lung cancer

Legal Events

Date Code Title Description
8364 No opposition during term of opposition